New injection aims to tackle fatty liver

NCT ID NCT06891365

Recruiting now Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests an experimental drug called NNC0581-0001 in 48 adults with fatty liver and suspected liver inflammation. Participants receive three monthly injections of either the drug or a placebo. The main goal is to check safety and how the drug moves through the body, not yet to prove it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NNC0581-0001 (an experimental drug injected under the skin)
What this could lead to: If successful, this could point toward a new treatment to reduce liver fat and inflammation in fatty liver disease.
What could go wrong: This is a very early Phase 1 trial with only 48 people, focused on safety. The drug may not work or could have side effects. It will take years before any treatment is available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fatty liver disease metabolic dysfunction-associated steatohepatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS HEPATIC STEATOSIS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Parexel Research Unit
RECRUITING

Harrow, HA1 3UJ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.